Newly identified potential issues with CRISPR-Cas9 gene editing aren't as worrisome as you might think.
These stocks have what it takes to help meet your financial needs in retirement beyond what Social Security can provide.
This tech company is quietly transforming into an innovator once again, delivering growing income that isn't showing any signs of stopping.
All three of these bargains have forward P/E ratios of less than eight.
They may not be leading the market right now, but if history is any guide, then value stocks are poised to outperform. Here's why...
A few surprising aspects about the $1.2 trillion market for food on the go.
There's no limit to where and how far this $2 billion company can go -- it's a $100 billion industry leading blue-chip in the making.
Which cloud-based healthcare technology stock wins in a head-to-head matchup?
These two drug stocks have a lot to offer income investors and value investors.
Want Netflix or Amazon-type gains? This report is your best shot.